GlassScriptPhysician profile
Douglas Jonathan Guevara
NPI 1568923043
$5,356.03
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.93 · 2020: $26.57 · 2021: $1,958 · 2022: $2,539 · 2023: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $685.32 | 2021-2023 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $569.32 | 2021-2023 | Farxiga |
| Mannkind Corporation | $527.00 | 2021-2023 | Afrezza |
| Sanofi-Aventis U.S. LLC | $406.75 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $381.74 | 2021-2023 | Gvoke Hypopen |
| Novo Nordisk INC | $284.18 | 2022-2023 | Rybelsus, Ozempic, Wegovy |
| Esperion Therapeutics, INC. | $221.93 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.82 | 2021-2023 | Jardiance |
| Amgen INC. | $207.14 | 2022-2023 | Repatha, Otezla |
| Abbvie INC. | $191.03 | 2021-2023 | |
| Dexcom, INC. | $182.86 | 2021-2023 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $142.25 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Abbott Laboratories | $141.85 | 2023 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $133.35 | 2021-2023 | |
| Lifescan, INC. | $110.96 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $106.87 | 2021-2022 | |
| Intuity Medical INC | $100.84 | 2022 | |
| Zealand Pharma US, INC. | $87.44 | 2021-2022 | |
| Becton, Dickinson and Company | $82.14 | 2022 | |
| Merck Sharp & Dohme LLC | $73.46 | 2019-2022 | |
| Radius Health, INC. | $70.53 | 2022-2023 | |
| Corcept Therapeutics | $67.86 | 2021-2023 | Korlym |
| Insulet Corporation | $48.32 | 2022 | |
| Tandem Diabetes Care, INC. | $46.97 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $41.92 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $37.91 | 2021 | |
| Ibsa Pharma INC. | $30.09 | 2021-2023 | Tirosint, Licart |
| Cequr Corporation | $28.55 | 2023 | Cequr Simplicity |
| Pfizer INC. | $26.28 | 2022 | |
| Exact Sciences Corporation | $20.92 | 2023 | Cologuard Collection Kit |
| Eusa Pharma (US) LLC | $20.66 | 2022 | |
| Recordati_rare_diseases_inc. | $20.66 | 2022 | |
| Embecta Corp. | $17.50 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Roche Diabetes Care, INC. | $16.20 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Guevara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.